Previous close | 165.54 |
Open | 166.03 |
Bid | 0.00 x 900 |
Ask | 0.00 x 1200 |
Day's range | 163.89 - 166.34 |
52-week range | 155.72 - 186.69 |
Volume | |
Avg. volume | 7,073,747 |
Market cap | 430.37B |
Beta (5Y monthly) | 0.57 |
PE ratio (TTM) | 24.46 |
EPS (TTM) | 6.73 |
Earnings date | 18 Apr 2023 |
Forward dividend & yield | 4.52 (2.74%) |
Ex-dividend date | 17 Feb 2023 |
1y target est | 183.63 |
In fact, two stocks that outperformed the S&P 500 last year are now down more than 6% since the start of the year: Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV).. Motley Fool contributors Adria Cimino and Keith Speights talk about why these two stocks actually make great buys right now. Adria Cimino (Johnson & Johnson): J&J may have disappointed investors when it reported fourth-quarter earnings on Jan. 24.
Any time is a good time to buy solid dividend stocks. Here's why they chose Abbott Laboratories (NYSE: ABT), AbbVie (NYSE: ABBV), and Johnson & Johnson (NYSE: JNJ). David Jagielski (Abbott Laboratories): One dividend stock that should be attractive to long-term investors is Abbott Laboratories.
Out of the Dow Jones Industrial Average's 30 components, there are three amazing deals hiding in plain sight.